These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts. Fuka G; Kantner HP; Grausenburger R; Inthal A; Bauer E; Krapf G; Kaindl U; Kauer M; Dworzak MN; Stoiber D; Haas OA; Panzer-Grümayer R Leukemia; 2012 May; 26(5):927-33. PubMed ID: 22094587 [TBL] [Abstract][Full Text] [Related]
4. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response. Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273 [TBL] [Abstract][Full Text] [Related]
5. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells. Barata JT; Silva A; Brandao JG; Nadler LM; Cardoso AA; Boussiotis VA J Exp Med; 2004 Sep; 200(5):659-69. PubMed ID: 15353558 [TBL] [Abstract][Full Text] [Related]
6. Involvement of PI3K-AKT-mTOR pathway in protein kinase CKII inhibition-mediated senescence in human colon cancer cells. Park JH; Kim JJ; Bae YS Biochem Biophys Res Commun; 2013 Apr; 433(4):420-5. PubMed ID: 23523798 [TBL] [Abstract][Full Text] [Related]
7. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy. Martelli AM; Tabellini G; Ricci F; Evangelisti C; Chiarini F; Bortul R; McCubrey JA; Manzoli FA Adv Biol Regul; 2012 Jan; 52(1):214-27. PubMed ID: 21983557 [No Abstract] [Full Text] [Related]
8. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319 [TBL] [Abstract][Full Text] [Related]
9. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Sekulić A; Hudson CC; Homme JL; Yin P; Otterness DM; Karnitz LM; Abraham RT Cancer Res; 2000 Jul; 60(13):3504-13. PubMed ID: 10910062 [TBL] [Abstract][Full Text] [Related]
10. The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells. Lau MT; Leung PC Cancer Lett; 2012 Dec; 326(2):191-8. PubMed ID: 22922215 [TBL] [Abstract][Full Text] [Related]
11. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907 [TBL] [Abstract][Full Text] [Related]
12. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK. Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225 [TBL] [Abstract][Full Text] [Related]
13. Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation. Calviño E; Estañ MC; Simón GP; Sancho P; Boyano-Adánez Mdel C; de Blas E; Bréard J; Aller P Biochem Pharmacol; 2011 Dec; 82(11):1619-29. PubMed ID: 21889928 [TBL] [Abstract][Full Text] [Related]
14. Copper ions strongly activate the phosphoinositide-3-kinase/Akt pathway independent of the generation of reactive oxygen species. Ostrakhovitch EA; Lordnejad MR; Schliess F; Sies H; Klotz LO Arch Biochem Biophys; 2002 Jan; 397(2):232-9. PubMed ID: 11795876 [TBL] [Abstract][Full Text] [Related]
15. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum. Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948 [TBL] [Abstract][Full Text] [Related]
16. TOR kinase and Ran are downstream from PI3K/Akt in H2O2-induced mitosis. Radisavljevic ZM; González-Flecha B J Cell Biochem; 2004 Apr; 91(6):1293-300. PubMed ID: 15048882 [TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effect of brain-derived neurotrophic factor mediated by autophagy through the PI3K/Akt/mTOR pathway. Chen A; Xiong LJ; Tong Y; Mao M Mol Med Rep; 2013 Oct; 8(4):1011-6. PubMed ID: 23942837 [TBL] [Abstract][Full Text] [Related]
18. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803 [TBL] [Abstract][Full Text] [Related]
19. A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling. Yuan Y; Zhang A; Huang S; Ding G; Chen R Am J Physiol Renal Physiol; 2011 Feb; 300(2):F393-402. PubMed ID: 21123490 [TBL] [Abstract][Full Text] [Related]